Peptides Similar to VIP

Peptides Related to VIP#

Vasoactive Intestinal Peptide belongs to the secretin/glucagon superfamily of peptide hormones and neuropeptides. Several members of this family share structural homology, overlapping receptor pharmacology, and related biological activities. Understanding the similarities and differences among these peptides is essential for interpreting VIP research and evaluating potential therapeutic approaches.

The closest relatives of VIP within this superfamily are PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, and PHI/PHM-27 (peptide histidine isoleucine/peptide histidine methionine). Each of these peptides shares ancestry with VIP, signals through class B G-protein coupled receptors, and participates in overlapping physiological processes, but each also possesses distinct receptor selectivity patterns and tissue-specific functions.

PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide)#

PACAP is the closest functional and structural relative of VIP. Discovered in 1989 by Arimura and colleagues, PACAP exists in two biologically active forms: PACAP-38 (38 amino acids) and PACAP-27 (the N-terminal 27 residues of PACAP-38). The 27-residue form of PACAP shares 68% sequence identity with VIP, with 19 of 27 positions being identical or conservatively substituted. The first six N-terminal residues of PACAP-27 (HSDGIF) differ from VIP (HSDAVF) at only two positions (positions 4 and 5), explaining the shared receptor pharmacology.

Receptor Selectivity#

The critical pharmacological distinction between VIP and PACAP lies in their receptor selectivity profiles. Both peptides bind VPAC1 and VPAC2 receptors with comparable low nanomolar affinity. However, PACAP additionally binds the PAC1 receptor with high affinity (Kd approximately 0.5 nM), whereas VIP binds PAC1 with 100 to 1000-fold lower affinity. This means PACAP engages three receptor subtypes while VIP effectively activates only two. PAC1 is abundantly expressed in the brain, adrenal medulla, and certain peripheral tissues, giving PACAP a broader signaling repertoire, particularly in neuronal systems.

PAC1 receptor activation by PACAP triggers not only Gs/cAMP signaling but also robust Gq/PLC/calcium responses and direct activation of ion channels in neurons, contributing to effects on neurotransmitter release, synaptic plasticity, and neuronal survival that may exceed those achievable through VPAC receptor activation alone.

Comparative Biology#

In neuroprotection research, both VIP and PACAP demonstrate protective effects against excitotoxicity, oxidative stress, and ischemia-reperfusion injury. However, PACAP is generally reported to be more potent in neuronal injury models, an advantage attributed to its additional PAC1-mediated signaling. PACAP has also been more extensively studied in migraine pathophysiology, where PAC1 receptor activation in trigeminovascular neurons is believed to contribute to migraine pathogenesis. This has led to the development of PAC1-targeting antibodies for migraine prevention, a pathway not relevant to VIP.

In immune regulation, VIP and PACAP produce largely overlapping anti-inflammatory and immunomodulatory effects, primarily mediated through VPAC1 on immune cells. Both suppress macrophage activation, inhibit pro-inflammatory cytokine production, and promote regulatory T-cell differentiation. The immune effects are difficult to dissect pharmacologically because both peptides activate the same VPAC receptors on immune cells with similar potency.

Both peptides share the limitation of extremely short circulating half-lives (VIP approximately 1-2 minutes; PACAP similarly rapid), driven by analogous enzymatic degradation pathways involving NEP and DPP-IV.

Secretin#

Secretin is the founding member of the secretin/glucagon superfamily, discovered by Bayliss and Starling in 1902 as the first hormone identified. It is a 27-amino acid peptide that shares approximately 50% sequence homology with VIP. Like VIP, secretin signals through a class B GPCR, but it binds primarily to its own dedicated receptor, the secretin receptor (SCTR), rather than to VPAC1 or VPAC2. Secretin has low affinity for VPAC receptors, and VIP conversely has negligible affinity for SCTR.

Functional Divergence#

Despite their structural relationship, VIP and secretin have largely distinct physiological roles. Secretin functions predominantly as a gastrointestinal hormone, released from S-cells of the duodenal mucosa in response to gastric acid, where it stimulates pancreatic bicarbonate secretion and inhibits gastric acid output. Its role as a neurotransmitter in the central nervous system is far more limited than that of VIP, although secretin-containing neurons have been identified in certain brain regions including the cerebellum and hypothalamus.

Secretin lacks the potent vasodilatory, immunomodulatory, and neuroprotective properties that characterize VIP. While secretin can produce modest vasodilation and has been investigated in autism spectrum disorder research based on anecdotal reports (which were not confirmed in controlled trials), its therapeutic profile does not overlap meaningfully with VIP's principal applications in pulmonary hypertension, neuroprotection, or immune modulation.

Clinical Status#

Secretin holds a significant advantage over VIP in terms of regulatory status. Synthetic secretin (SecreFlo/ChiRhoStim) is FDA-approved as a diagnostic agent for evaluating pancreatic exocrine function and for the diagnosis of gastrinoma (Zollinger-Ellison syndrome). This approval reflects secretin's well-characterized and narrow physiological role, which lends itself to targeted diagnostic application. VIP, by contrast, has not achieved regulatory approval for any indication despite its broader range of preclinical evidence.

PHI/PHM-27 (Peptide Histidine Isoleucine/Peptide Histidine Methionine)#

PHI (in rodents) and PHM-27 (in humans) are 27-amino acid peptides that are co-encoded with VIP on the same preproprotein gene. Both are processed from the VIP precursor by prohormone convertases and are co-stored and co-released with VIP from the same secretory granules. The human form, PHM-27, takes its name from its N-terminal histidine and C-terminal methionine residues, while the rodent form PHI has isoleucine at the C-terminus.

Structural and Pharmacological Relationship#

PHM-27 shares approximately 48% sequence identity with VIP and activates the same VPAC1 and VPAC2 receptors. However, PHM-27 binds these receptors with substantially lower affinity than VIP, typically 5-10 fold lower at VPAC1 and 10-50 fold lower at VPAC2. This reduced affinity translates to lower potency in most biological assays, including cAMP generation, vasodilation, and bronchodilation.

Because PHM-27 is always co-released with VIP, it is difficult to isolate its independent physiological contribution from that of VIP. In most experimental settings, the biological effects of VIP neuron activation are attributed primarily to VIP itself, with PHM-27 considered a supplementary agonist that may modulate the magnitude or duration of VIP-initiated responses. Some evidence suggests that PHM-27 may have distinct local effects in specific tissues, particularly in the gastrointestinal tract, but these have not been well characterized.

Research Significance#

PHM-27 has received minimal independent research attention and no independent therapeutic development. Its primary significance lies in the understanding of VIP neurobiology: the co-release of PHM-27 with VIP means that any physiological or experimental activation of VIP neurons produces simultaneous exposure to both peptides. Researchers studying VIP signaling in vivo must account for this co-release when attributing observed effects specifically to VIP.

Broader Superfamily Context#

Beyond the three peptides discussed above, VIP shares more distant homology with several other members of the secretin/glucagon superfamily. These include glucagon, GLP-1, GLP-2, GIP, and GHRH. While these peptides share the ancestral structural template and class B GPCR signaling mechanism, their receptor selectivity and physiological roles diverge substantially from VIP.

GLP-1 is noteworthy as a metabolic peptide with an established therapeutic role (GLP-1 receptor agonists such as semaglutide and liraglutide are approved for diabetes and obesity), demonstrating that the pharmacokinetic limitations common to the superfamily (short half-life, rapid degradation) can be overcome through systematic analog development. The success of GLP-1 analog engineering provides a conceptual framework for VIP analog development, though the challenge is greater for VIP given its two-receptor pharmacology and broader tissue distribution.

Comparative Receptor Selectivity#

The following table summarizes the receptor binding profiles of VIP and its closest superfamily relatives.

Key Distinguishing Features#

Several features distinguish VIP from its superfamily relatives in the context of therapeutic research:

• Dual VPAC agonism without PAC1 activation: VIP's receptor profile allows activation of both VPAC1-mediated immune modulation and VPAC2-mediated smooth muscle and circadian effects, without the PAC1-dependent neuronal excitation and potential migraine-promoting effects associated with PACAP. This profile may be advantageous for anti-inflammatory and vasodilatory applications.

• Potent vasodilation: VIP is among the most potent endogenous vasodilators, exceeding secretin and PHM-27 in this regard and comparable to PACAP. This property underlies its investigation in pulmonary arterial hypertension but also represents a dose-limiting side effect for systemic applications.

• Pleiotropic anti-inflammatory activity: VIP's engagement of VPAC1 on macrophages, dendritic cells, and T lymphocytes produces broad anti-inflammatory and tolerogenic effects that are shared with PACAP but largely absent from secretin's pharmacological profile.

• Circadian regulation: VIP's role in synchronizing suprachiasmatic nucleus oscillators through VPAC2 is a distinctive function not shared by secretin or PHM-27, though PACAP also acts within the SCN as an input signal for photic entrainment via PAC1.

Evidence Gaps in Comparative Research#

Direct head-to-head comparisons between VIP and its superfamily relatives in standardized experimental models are limited. Most of the comparative pharmacology derives from in vitro receptor binding and cAMP assays, with far less systematic comparison of in vivo efficacy across therapeutic indications. The development of receptor-selective analogs for each VPAC subtype and PAC1 would greatly advance the ability to dissect the relative contributions of each receptor pathway to the therapeutic effects observed with native VIP and PACAP.

Related Reading#

• VIP overview and research guide
• VIP research evidence
• VIP dosing protocols